Literature DB >> 15981817

Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.

Michelle Dolan1, Dale Snover.   

Abstract

Because HER-2 expression in invasive carcinoma of the breast has well-documented ramifications for treatment and prognosis, accurate assessment of HER-2 status is critical. Comparative studies have shown high concordance rates between immunohistochemical analysis and fluorescence in situ hybridization (FISH) in cases with immunohistochemical scores of 0 or 1+ (negative) and 3+ (strongly positive) and low concordance rates among cases with immunohistochemical scores of 2+. The present study was performed to determine concordance rates in a setting more representative of routine clinical practice, in which multiple pathologists submit specimens to a single cytogenetics referral laboratory. We found a higher rate of discordance between immunohistochemical analysis and FISH (approximately 92%) in the groups with immunohistochemical scores of 2+ than reported in other studies. These results strongly support the practice of performing FISH in all cases with immunohistochemical scores of 2+, particularly in routine practice, in which interobserver variability in immunohistochemical scoring among multiple pathologists is likely to be high.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981817

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

1.  Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?

Authors:  Ciara Barrett; Hilary Magee; Denise O'Toole; Sinead Daly; Michael Jeffers
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

2.  Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients.

Authors:  Lin Wang; Xiaobei Wang; Xiu Nie; Ling Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

Review 3.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.

Authors:  Nandini Dendukuri; Karim Khetani; Michelle McIsaac; James Brophy
Journal:  CMAJ       Date:  2007-05-08       Impact factor: 8.262

4.  HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.

Authors:  Saima Sharif; Ramesh K Ramanathan; Douglas Potter; Kathleen Cieply; Alyssa M Krasinskas
Journal:  Dig Dis Sci       Date:  2008-05-08       Impact factor: 3.199

5.  Immunohistochemical analysis of undifferentiated and poorly-differentiated head and neck malignancies at a tertiary hospital in Nigeria.

Authors:  Akinyele O Adisa; Abideen O Oluwasola; Bukola F Adeyemi; Bamidele Kolude; Effiong Eu Akang; Jonathan O Lawoyin
Journal:  Head Neck Oncol       Date:  2010-11-03

6.  Intratumoral Agreement of High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopic Profiles in the Metabolic Characterization of Breast Cancer.

Authors:  Vivian Youngjean Park; Dahye Yoon; Ja Seung Koo; Eun-Kyung Kim; Seung Il Kim; Ji Soo Choi; Seho Park; Hyung Seok Park; Suhkmann Kim; Min Jung Kim
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

7.  Estimation of T2* Relaxation Time of Breast Cancer: Correlation with Clinical, Imaging and Pathological Features.

Authors:  Mirinae Seo; Jung Kyu Ryu; Geon-Ho Jahng; Yu-Mee Sohn; Sun Jung Rhee; Jang-Hoon Oh; Kyu-Yeoun Won
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

8.  Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.

Authors:  Gulisa Turashvili; Samuel Leung; Dmitry Turbin; Kelli Montgomery; Blake Gilks; Rob West; Melinda Carrier; David Huntsman; Samuel Aparicio
Journal:  BMC Cancer       Date:  2009-05-29       Impact factor: 4.430

9.  Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer.

Authors:  Weiguo Sui; Minglin Ou; Jiejing Chen; Youhua Wan; Hongbo Peng; Minfang Qi; He Huang; Yong Dai
Journal:  World J Surg Oncol       Date:  2009-11-09       Impact factor: 2.754

10.  Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer.

Authors:  Shivang Doshi; David Ray; Karen Stein; Jie Zhang; Prasad Koduru; Franz Fogt; Axel Wellman; Ricky Wat; Charles Mathews
Journal:  Diagnostics (Basel)       Date:  2016-01-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.